Skip to main content
. 2022 Mar 15;208(6):1371–1377. doi: 10.4049/jimmunol.2100352

FIGURE 1.

FIGURE 1.

Anti-CD47 mAb treatment depletes splenic MZ B cells. WT C57BL/6 mice were injected with PBS, IgG isotype control, or anti-CD47 Ab i.p. as described in Materials and Methods. (A) Percentage of CD19+ splenic B cells. (B) FACS plots illustrating the gating strategy for MZ, MZ progenitor (MZP), and follicular (FOL) B cells. (C–E) Percentage of (C) MZ and MZP B cells and (D) FOL B cells in mice treated with PBS, IgG isotype control, or anti-CD47 Ab and (E) the ratio of FOL/MZ B cells in these mice. All data are representative of at least three independent experiments with three to five mice per group. Groups were compared with an unpaired, two-tailed t test with Welch’s correction. Data are presented as the mean ± SEM. (F) Representative images of immunofluorescence staining of MZ B cells in spleens of mice treated with PBS or anti-CD47 Ab. Sections were stained with AF647-conjugated rat anti-mouse CD1d mAb and DAPI. *p < 0.05, **p < 0.01; ns, not significant.